Amplyx Appoints Mirati’s Chris LeMasters as Chief Operating Officer

Amplyx Pharmaceuticals announced Monday the addition of Chris LeMasters to its C-suite as chief operating officer.

LeMasters most recently served as chief business officer at cancer drug developer Mirati Therapeutics (NASDAQ: [[ticker:MRTX]]), another San Diego-based biotech. He left Mirati in January after about three years there. His prior experience includes senior management roles at Promosome, Tragara Pharmaceuticals, and Cabrellis Pharmaceuticals.

Amplyx, headed by CEO Ciara Kennedy, is advancing investigational treatments designed to combat fungal infections and other diseases for people with compromised immune systems, such as cancer and transplant patients.

Author: Sarah de Crescenzo

Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register. She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine.